Clindamycin for intraincisional antibiotic prophylaxis in dermatologic surgery.
OBJECTIVE
To assess the efficacy of intraincisional clindamycin therapy as an alternative to nafcillin treatment in decreasing the risk of postoperative wound infections in dermatologic surgery.


METHODS
Prospective, double-blinded, randomized, placebo-controlled trial conducted over a 7-month period.


METHODS
Three private practice Mohs micrographic surgery referral centers.


METHODS
A total of 1030 consecutive patients who underwent Mohs micrographic surgery with subsequent reconstruction.


METHODS
Prior to reconstruction, patients were randomly assigned to receive either intraincisional buffered lidocaine with epinephrine containing clindamycin or buffered lidocaine with epinephrine without clindamycin. Nurses and physicians who scored the wound at follow-up were blinded to the treatment conditions.


METHODS
Surgical wounds evaluated at the time of suture removal were scored according to a standardized assessment based on erythema, edema, and the presence of purulent discharge. Wounds scored 4 or higher were considered to be infected. Bacterial cultures obtained when indicated were also compared.


RESULTS
Of the 1172 surgical wounds included in the study, 29 had wound scores of 4 or higher, 6 in the study group and 23 in the control group (P =.001, Fisher exact test). Of these 29, 18 had culture-positive infections. Four of these occurred in the study group, and 14 occurred in the control group (P =.02, Fisher exact test).


CONCLUSIONS
The results of this study further support the efficacy of single-dose preoperative intraincisional antibiotic treatment for dermatologic surgery. With the relatively high prevalence of patient-reported penicillin allergies, buffered lidocaine containing clindamycin offers an inexpensive, safe, convenient, and effective alternative.
Huether
Michael J
MJ
mjhah@gci-net.com
Griego
Robert D
RD
Brodland
David G
DG
Zitelli
John A
JA
D000328:Adult; D000368:Aged; D019072:Antibiotic Prophylaxis; D002981:Clindamycin / Q000008:administration & dosage*; D003880:Dermatology / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D015580:Mohs Surgery / Q000379:methods*; D011300:Preoperative Care; D011336:Probability; D011446:Prospective Studies; D019651:Plastic Surgery Procedures / Q000379:methods; D012016:Reference Values; D018709:Statistics, Nonparametric; D013530:Surgical Wound Infection / Q000517:prevention & control*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
D002981:Clindamycin